Effect of Reduction of Inflammatory Status on Glucose Metabolism in Overweight Men
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00221052|
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : October 11, 2006
Overweight increases the risk to develop chronic diseases including type-2 diabetes and cardiovascular disease. The low-grade inflammatory status often seen in overweight subjects is thought to play an important role in disease development.
The purpose of this study is to determine the role of inflammation on glucose metabolism and insulin resistance. In this study the effect of the anti-inflammatory treatment diclofenac on markers of inflammation and on parameters of glucose metabolism will be studied.
|Condition or disease||Intervention/treatment|
|Overweight Obesity Inflammation||Drug: Diclofenac|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Relation Between Reduction of the Inflammatory Status and Glucose Metabolism in Healthy Overweight Men|
|Study Start Date :||June 2005|
|Estimated Study Completion Date :||July 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00221052
|TNO Quality of Life|
|Zeist, Netherlands, 3700 AJ|
|Principal Investigator:||Trinette van Vliet, PhD||TNO Quality of Life, Location Zeist|